Boston Scientific Beats on Both Top and Bottom Lines

Seth Jayson, The Motley Fool
Updated

Boston Scientific (NYS: BSX) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Boston Scientific beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share expanded. GAAP earnings per share expanded.


Margins increased across the board.

Revenue details
 Boston Scientific reported revenue of $1.81 billion. The 20 analysts polled by S&P Capital IQ foresaw revenue of $1.78 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.12. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.09 per share. Non-GAAP EPS of $0.12 for Q2 were 9.1% higher than the prior-year quarter's $0.11 per share. GAAP EPS were $0.10 for Q2 versus -$2.51 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 68.1%, 220 basis points better than the prior-year quarter. Operating margin was 13.7%, 20 basis points better than the prior-year quarter. Net margin was 7.2%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $1.71 billion. On the bottom line, the average EPS estimate is $0.09.

Next year's average estimate for revenue is $7.06 billion. The average EPS estimate is $0.41.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 752 members out of 937 rating the stock outperform, and 185 members rating it underperform. Among 192 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 175 give Boston Scientific a green thumbs-up, and 17 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $9.17.

Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Boston Scientific Beats on Both Top and Bottom Lines originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement